EUCTR2011-000828-15-DE进行中（未招募）不适用
A Prospective, Randomized, Double-Blind Comparisonof a Long-Acting Basal Insulin Analog LY2963016 toLantus® in Adult Patients with Type 2 Diabetes Mellitus - The ELEMENT 2 Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 792
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Have T2DM based on the disease diagnostic criteria World Health Organization (WHO) classification.
- •[2] Are =18 years of age.
- •[3] Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to Visit 1, with or without Lantus. Note: use and dose of oral agents in combination with insulin must be in accordance with the local product label. Patients taking metformin and who are found to have a contraindicated serum creatinine level (=1.4 mg/dL [123.8 µmol/L] for females, =1.5 mg/dL [132.6 µmol/L] for males, or based on country-specific label) must be willing to discontinue use of metformin at randomization.
- •Note: Sitagliptin is the only DPP-IV inhibitor currently approved for use with insulin.
- •If on two OAMs at study entry and there is a need to discontinue one of those agents due to country labeling requirements or clinical parameters, that patient would not meet entry criteria.
- •[4] Have an HbA1c =7.0% and =11.0% if insulin naïve; if previously on Lantus, then HbA1c =11.0%.
- •[5] Body mass index (BMI) =45 kg/m2.
- •[6] As determined by the investigator, are capable and willing to do the following:
- •? perform SMBG
- •? complete patient diaries as instructed
- •? use covered insulin vial and syringe according to study instructions
- •? are receptive to diabetes education
- •? comply with required study treatment and study visits.
- •[7] Have given written informed consent to participate in this study in accordance with local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[8] Have used any other insulin except Lantus, including commercial and investigational insulins within the previous 30 days.
- •[9] Have been exposed to a biosimilar insulin glargine within the previous 90 days.
- •[10] Have a history of taking basal bolus therapy or who, in the investigator's opinion, require mealtime insulin in order to achieve target control.
- •[11] Have used short-acting glucagon like peptide (GLP-1) agonist (eg, exenatide) or long-acting GLP-1 agonist (eg, liraglutide) within the previous 90 days.
- •[12] Have used pramlintide (eg, Symlin®) within the previous 30 days.
- •[13] Have excessive insulin resistance at study entry (total insulin dose =1.5 U/kg).
- •[14] Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
- •[15] Have known hypersensitivity or allergy to Lantus or its excipients.
- •[16] Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy at pharmacological doses (excluding topical, intraarticular, intraocular, or inhaled preparations and physiologic replacement doses for adrenal deficiency) or have received such therapy within 4 weeks immediately preceding Visit 1.
- •[17] Have obvious signs or symptoms, or laboratory evidence, of liver disease (alanine aminotransferase [ALT]; or aspartate aminotransferase [AST] greater than 2.5 times the upper limit of the reference range, as defined by the central laboratory; or albumin value remarkably above or below the normal reference range, as defined by the central laboratory).
- •[18] Have one of the following concomitant diseases: significant cardiac (eg, congestive heart failure Class III or IV) or gastrointestinal disease (eg, significant gastroparesis).
- •[19] Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 mg/dL
- •[20] Have had a blood transfusion or severe blood loss within 3 months prior to Visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
- •[21] Patients with active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ).
- •[22] Are investigator-site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •[23] Have any other condition (including known drug or alcohol abuse or
- •psychiatric disorder) that precludes the patient from following and completing
- •the protocol.
- •[24] Are Lilly employees.
- •[25] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device other than LY2963016, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- •[26] Have previously completed or withdrawn from this study.
- •[27] Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.
- •[28] Women who are breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.Type 1 DiabetesMedDRA version: 20.1 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861EUCTR2015-005356-99-DEEli Lilly and Company1,567
进行中（未招募）
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER1,392
进行中（未招募）
1 期
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.MedDRA version: 20.1 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861Type 1 DiabetesEUCTR2015-005356-99-ATEli Lilly and Company1,567
进行中（未招募）
1 期
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-002371-18-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER751
进行中（未招募）
不适用
A Prospective, Randomized, Double-Blind Comparisonof a Long-Acting Basal Insulin Analog LY2963016 toLantus® in Adult Patients with Type 2 Diabetes Mellitus - The ELEMENT 2 StudyEUCTR2011-000828-15-PLEli Lilly and Company792